Health Care & Life Sciences » Pharmaceuticals | C4X Discovery Holdings PLC

C4X Discovery Holdings PLC | Balance Sheet

Fiscal year is August-July. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,514.00
673.00
7,485.00
1,328.00
6,031.00
5,578
Total Accounts Receivable
408.00
379.00
916.00
1,684.00
2,048.00
1,489
Other Current Assets
25.00
28.00
172.00
145.00
200.00
265
Total Current Assets
1,947.00
1,080.00
8,573.00
3,157.00
8,279.00
7,332
Net Property, Plant & Equipment
23.00
21.00
85.00
94.00
90.00
83
Intangible Assets
60.00
56.00
59.00
1,846.00
1,762.00
1,625
Total Assets
2,030.00
1,157.00
8,717.00
5,097.00
10,131.00
9,040
ST Debt & Current Portion LT Debt
-
30.00
-
-
-
Accounts Payable
69.00
107.00
448.00
392.00
700.00
Other Current Liabilities
58.00
133.00
301.00
400.00
371.00
Total Current Liabilities
127.00
270.00
749.00
792.00
1,071.00
Long-Term Debt
2,144.00
2,220.00
-
-
-
Total Liabilities
2,271.00
2,490.00
749.00
792.00
1,071.00
Common Equity (Total)
241.00
1,333.00
7,968.00
4,305.00
9,060.00
Total Shareholders' Equity
241.00
1,333.00
7,968.00
4,305.00
9,060.00
Total Equity
241.00
1,333.00
7,968.00
4,305.00
9,060.00
Liabilities & Shareholders' Equity
2,030.00
1,157.00
8,717.00
5,097.00
10,131.00

About C4X Discovery Holdings

View Profile
Address
Manchester One
Manchester Greater Manchester M1 3LD
United Kingdom
Employees -
Website http://c4xdiscovery.com/
Updated 07/08/2019
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. Its software platforms consists of Taxonomy3, which utilizes a mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases; and Conformetrix, which determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom.